Catalent, with its 50 global facilities, has been an industry leader in manufacturing GLP-1 drugs, including Novo’s own Ozempic and Wegovy. Since 2017, Catalent has been one of the few CDMOs ...

Novo Holdings is encountering more resistance as it aims to close its $16.5 billion acquisition of pharma manufacturing giant Catalent by the end of the year. A dozen consumer groups and trade ...

Roche CEO: not good to limit competition in this space Roche says not itself, but others affected by Catalent deal Swiss drugmaker joins US peer Lilly in voicing opposition Eli Lilly and advocacy ...

Nov 5 (Reuters) - Contract drug manufacturer Catalent (CTLT.N), opens new tab, which is in the process of being acquired by Novo Holdings, posted a surprise first-quarter loss and revenue below ...

At the same time, Catalent is one of the “very few” contract drug manufacturers that provides specialized development and manufacturing services to companies that sell these medicines.

While the deal would not weigh heavily on Roche’s own production operations, “it could be a problem for other smaller players if there is a restriction in terms of how many CMOs are available ...